Literature DB >> 19620333

In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Morris O Makobongo1, Tchelet Kovachi, Hanan Gancz, Amram Mor, D Scott Merrell.   

Abstract

The gastric pathogen Helicobacter pylori has developed resistance to virtually all current antibiotics; thus, there is a pressing need to develop new anti-H. pylori therapies. The goal of this work was to evaluate the antibacterial effect of oligo-acyl-lysyl (OAK) antimicrobial peptidomimetics to determine if they might represent alternatives to conventional antibiotic treatment of H. pylori infection. A total of five OAK sequences were screened for growth-inhibitory and/or bactericidal effects against H. pylori strain G27; four of these sequences had growth-inhibitory and bactericidal effects. The peptide with the highest efficacy against strain G27, C12K-2beta12, was selected for further characterization against five additional H. pylori strains (26695, J99, 7.13, SS1, and HPAG1). C12K-2beta12 displayed MIC and minimum bactericidal concentration (MBC) ranges of 6.5 to 26 microM and 14.5 to 90 microM, respectively, across the six strains after 24 h of exposure. G27 was the most sensitive H. pylori strain (MIC = 6.5 to 7 microM; MBC = 15 to 20 microM), whereas 26695 was the least susceptible strain (MIC = 25 to 26 microM; MBC = 70 to 90 microM). H. pylori was completely killed after 6 to 8 h of incubation in liquid cultures containing two times the MBC of C12K-2beta12. The OAK demonstrated strong in vitro stability, since efficacy was maintained after incubation at extreme temperatures (4 degrees C, 37 degrees C, 42 degrees C, 50 degrees C, 55 degrees C, 60 degrees C, and 95 degrees C) and at low pH, although reduced killing kinetics were observed at pH 4.5. Additionally, upon transient exposure to the bacteria, C12K-2beta12 showed irreversible and significant antibacterial effects and was also nonhemolytic. Our results show a significant in vitro effect of C12K-2beta12 against H. pylori and suggest that OAKs may be a valuable resource for the treatment of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620333      PMCID: PMC2764229          DOI: 10.1128/AAC.00510-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  81 in total

Review 1.  Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides.

Authors:  Y Shai
Journal:  Biochim Biophys Acta       Date:  1999-12-15

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes.

Authors:  Evgenia Glukhov; Margareta Stark; Lori L Burrows; Charles M Deber
Journal:  J Biol Chem       Date:  2005-07-25       Impact factor: 5.157

4.  Generation times of Proteus mirabilis and Escherichia coli in experimental infections.

Authors:  W W Eudy; S E Burrous
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

5.  The true division and death rates of Salmonella typhimurium in the mouse spleen determined with superinfecting phage P22.

Authors:  J Maw; G G Meynell
Journal:  Br J Exp Pathol       Date:  1968-12

6.  Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens.

Authors:  Jörg Andrä; Daniel Monreal; Guillermo Martinez de Tejada; Claudia Olak; Gerald Brezesinski; Susana Sanchez Gomez; Torsten Goldmann; Rainer Bartels; Klaus Brandenburg; Ignacio Moriyon
Journal:  J Biol Chem       Date:  2007-03-27       Impact factor: 5.157

7.  High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong.

Authors:  W H Wang; B C Wong; A K Mukhopadhyay; D E Berg; C H Cho; K C Lai; W H Hu; F M Fung; W M Hui; S K Lam
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

8.  Antiplasmodial activity of lauryl-lysine oligomers.

Authors:  I Radzishevsky; M Krugliak; H Ginsburg; A Mor
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

9.  One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.

Authors:  Stephan Miehlke; Wulf Schneider-Brachert; Christian Kirsch; Andrea Morgner; Ahmed Madisch; Eberhard Kuhlisch; Christian Haferland; Elke Bästlein; Claus Jebens; Christian Zekorn; Holger Knoth; Manfred Stolte; Norbert Lehn
Journal:  Helicobacter       Date:  2008-02       Impact factor: 5.753

10.  The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections.

Authors:  Brian J McMahon; Thomas W Hennessy; J Michael Bensler; Dana L Bruden; Alan J Parkinson; Julie M Morris; Alisa L Reasonover; Debby A Hurlburt; Michael G Bruce; Frank Sacco; Jay C Butler
Journal:  Ann Intern Med       Date:  2003-09-16       Impact factor: 25.391

View more
  12 in total

1.  Experimental conditions that enhance potency of an antibacterial oligo-acyl-lysyl.

Authors:  Yair Goldfeder; Fadia Zaknoon; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 2.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

3.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 4.  Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.

Authors:  Natalia Molchanova; Paul R Hansen; Henrik Franzyk
Journal:  Molecules       Date:  2017-08-29       Impact factor: 4.411

5.  Recombinant Expression of a Putative Amidase Cloned from the Genome of Listeria monocytogenes that Lyses the Bacterium and its Monolayer in Conjunction with a Protease.

Authors:  Mustafa Simmons; Cesar A Morales; Brian B Oakley; Bruce S Seal
Journal:  Probiotics Antimicrob Proteins       Date:  2012-03       Impact factor: 4.609

6.  Recombinant expression of two bacteriophage proteins that lyse clostridium perfringens and share identical sequences in the C-terminal cell wall binding domain of the molecules but are dissimilar in their N-terminal active domains.

Authors:  Mustafa Simmons; David M Donovan; Gregory R Siragusa; Bruce S Seal
Journal:  J Agric Food Chem       Date:  2010-10-13       Impact factor: 5.279

7.  Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model.

Authors:  Jayaram Lakshmaiah Narayana; Han-Ning Huang; Chang-Jer Wu; Jyh-Yih Chen
Journal:  Oncotarget       Date:  2015-05-30

8.  Unveiling the Crucial Role of Type IV Secretion System and Motility of Helicobacter pylori in IL-1β Production via NLRP3 Inflammasome Activation in Neutrophils.

Authors:  Ah-Ra Jang; Min-Jung Kang; Jeong-Ih Shin; Soon-Wook Kwon; Ji-Yeon Park; Jae-Hun Ahn; Tae-Sung Lee; Dong-Yeon Kim; Bo-Gwon Choi; Myoung-Won Seo; Soo-Jin Yang; Min-Kyoung Shin; Jong-Hwan Park
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

9.  In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.

Authors:  Morris O Makobongo; Leo Einck; Richard M Peek; D Scott Merrell
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

10.  The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner.

Authors:  Rasmus Bojsen; Rasmus Torbensen; Camilla Eggert Larsen; Anders Folkesson; Birgitte Regenberg
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.